Arrcus expands its footprint in the Japanese networking market

Arrcus, the hyperscale networking software company and a leader in core, edge, and multi-cloud routing and switching infrastructure, today announced a major milestone in the form of partnerships with ITOCHU Techno-Solutions Corporation, NEC Networks & System Integration Corporation (NESIC ) and APRESIA in its expansion in the Japan market to more broadly deliver cutting-edge networking solutions. These partnerships build on the recent investment in Arrcus from Hitachi Ventures as well as Arrcus’ collaboration on the SRv6 MUP initiative with SoftBank.

"We are thrilled to witness the rapid adoption of Arrcus’ networking solutions in Japan for 5G and datacenter routing and switching built on our industry-leading ArcOS platform and are excited to launch our partnerships with ITOCHU Techno-Solutions Corporation, NESIC, and APRESIA," said Shekar Ayyar, Chairman and CEO of Arrcus. "As we continue to revolutionize networking infrastructure, our focus remains on delivering cost-effective and highly performant networking solutions."

Arrcus delivers innovative software-driven network infrastructure solutions for routing and switching that enable Telco/5G, cloud, and enterprise customers to build and operate their networks and datacenters in a cost-effective and easily programmable manner. Customers can deploy new network functions and services faster and more securely, without being held back by rigid networking constraints from incumbent vendors. Partnerships with leading Japanese solution providers are an exciting step in expanding the reach of Arrcus to a wide range of customers in Japan. These partnerships build on the foundation of innovation that Arrcus has been creating with leading Japanese customers like SoftBank. As previously announced, the engagement with SoftBank has resulted in significant advancements in 5G with SRv6 Mobile User Plane (MUP) technology (*1) enabling the creation of new and innovative solutions for the Japan market that are now in commercial field trials (*2).